AP2012006343A0 - Neutralizing prolactin receptor antibodies and their therapeutic use. - Google Patents
Neutralizing prolactin receptor antibodies and their therapeutic use.Info
- Publication number
- AP2012006343A0 AP2012006343A0 AP2012006343A AP2012006343A AP2012006343A0 AP 2012006343 A0 AP2012006343 A0 AP 2012006343A0 AP 2012006343 A AP2012006343 A AP 2012006343A AP 2012006343 A AP2012006343 A AP 2012006343A AP 2012006343 A0 AP2012006343 A0 AP 2012006343A0
- Authority
- AP
- ARIPO
- Prior art keywords
- therapeutic use
- receptor antibodies
- prolactin receptor
- neutralizing prolactin
- neutralizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075546A EP2332995A1 (de) | 2009-12-10 | 2009-12-10 | Neutralisierende Prolactinrezeptor-Antikörper und deren therapeutische Verwendung |
| PCT/EP2010/067747 WO2011069799A1 (en) | 2009-12-10 | 2010-11-18 | Neutralizing prolactin receptor antibodies and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2012006343A0 true AP2012006343A0 (en) | 2012-06-30 |
Family
ID=42091520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2012006343A AP2012006343A0 (en) | 2009-12-10 | 2010-11-18 | Neutralizing prolactin receptor antibodies and their therapeutic use. |
Country Status (40)
| Country | Link |
|---|---|
| US (6) | US20120315276A1 (de) |
| EP (13) | EP2332995A1 (de) |
| JP (7) | JP6066474B2 (de) |
| KR (2) | KR101765968B1 (de) |
| CN (6) | CN102884082B (de) |
| AP (1) | AP2012006343A0 (de) |
| AR (6) | AR079348A1 (de) |
| AU (2) | AU2010330161B2 (de) |
| BR (2) | BR112012014048B1 (de) |
| CA (6) | CA2783610C (de) |
| CL (2) | CL2012001539A1 (de) |
| CR (2) | CR20120312A (de) |
| CU (2) | CU23973B1 (de) |
| CY (2) | CY1118209T1 (de) |
| DK (2) | DK2510002T3 (de) |
| DO (2) | DOP2012000160A (de) |
| EA (2) | EA028678B1 (de) |
| EC (2) | ECSP12011965A (de) |
| ES (2) | ES2603352T3 (de) |
| GT (1) | GT201200186A (de) |
| HK (2) | HK1180354A1 (de) |
| HR (2) | HRP20161401T1 (de) |
| HU (2) | HUE031631T2 (de) |
| IL (2) | IL220151A0 (de) |
| IN (2) | IN2012DN05078A (de) |
| LT (2) | LT2510002T (de) |
| MA (1) | MA33888B1 (de) |
| ME (1) | ME02577B (de) |
| MX (2) | MX2012006621A (de) |
| NZ (2) | NZ600512A (de) |
| PE (3) | PE20121561A1 (de) |
| PL (2) | PL2510006T3 (de) |
| PT (2) | PT2510006T (de) |
| RS (2) | RS55589B1 (de) |
| SG (2) | SG181513A1 (de) |
| SI (2) | SI2510006T1 (de) |
| TN (1) | TN2012000294A1 (de) |
| TW (5) | TW201130506A (de) |
| WO (6) | WO2011069798A1 (de) |
| ZA (2) | ZA201204214B (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332995A1 (de) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralisierende Prolactinrezeptor-Antikörper und deren therapeutische Verwendung |
| EP3345615B1 (de) | 2010-03-01 | 2019-10-16 | Bayer Healthcare LLC | Optimierte monoklonalantikörper gegen tissue factor pathway inhibitor (tfpi) |
| EP2530089A1 (de) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralisierender Antikörper Mat3 gegen den Prolactinrezeptor und dessen therapeutische Verwendung |
| BR112014022692A8 (pt) | 2012-03-14 | 2021-07-20 | Regeneron Pharma | molécula de ligação de antígeno multiespecífica |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| PL2935331T3 (pl) * | 2012-12-24 | 2018-07-31 | Abbvie Inc. | Białka wiążące receptor prolaktyny i ich zastosowania |
| TW201513882A (zh) * | 2013-03-15 | 2015-04-16 | Bayer Healthcare Llc | 抗－催乳激素受體抗體調配物 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| WO2015168474A1 (en) | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| JP2017536091A (ja) | 2014-10-02 | 2017-12-07 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 多価メディトープ、メディトープ結合性抗体およびそれらの使用 |
| EP3252074A4 (de) | 2015-01-30 | 2018-07-11 | Saitama Medical University | Anti-alk2-antikörper |
| WO2017007796A1 (en) | 2015-07-06 | 2017-01-12 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| JP7174699B2 (ja) | 2016-11-29 | 2022-11-17 | レゲネロン ファーマシューティカルス，インコーポレーテッド | Ｐｒｌｒ陽性乳癌の治療方法 |
| FR3062213B1 (fr) * | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| CN110785169A (zh) * | 2017-05-12 | 2020-02-11 | 千年制药公司 | 用三氮杂螺[4.5]癸酮治疗胃轻瘫 |
| KR20200027494A (ko) | 2017-07-10 | 2020-03-12 | 바이엘 파마 악티엔게젤샤프트 | 남성 및 여성 패턴 탈모를 위한 프로락틴 수용체 항체 |
| JP2021512899A (ja) | 2018-02-07 | 2021-05-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 治療用タンパク質送達のための方法および組成物 |
| WO2019169330A1 (en) * | 2018-03-02 | 2019-09-06 | Oncolix, Inc. | Method for treating cancers expressing prolactin receptor |
| CN109627340B (zh) * | 2018-12-05 | 2021-02-12 | 上海交通大学 | Cd3和prlr双特异性抗体及其构建与应用 |
| US10467487B1 (en) * | 2018-12-11 | 2019-11-05 | Chongqing Jinkang New Energy Automobile Co., Ltd. | Fusion-based traffic light recognition for autonomous driving |
| CN112425568A (zh) * | 2020-12-11 | 2021-03-02 | 上海市计划生育科学研究所 | 一种建立具有emt特征的良性前列腺增生bph犬模型的方法 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN114853890B (zh) * | 2022-03-16 | 2023-04-28 | 沈阳三生制药有限责任公司 | 一种prlr抗原结合蛋白及其制备方法和应用 |
| CN114634574B (zh) * | 2022-04-18 | 2022-12-20 | 先进生物(苏州)有限公司 | 抗B7H6的scFv抗体、其编码基因及其应用 |
| CN117285625B (zh) * | 2023-11-24 | 2024-01-23 | 南京佰抗生物科技有限公司 | 抗泌乳素蛋白的单克隆抗体及应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4986615A (en) | 1988-10-17 | 1991-01-22 | The Vendo Company | Vending apparatus |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| GB9105245D0 (en) * | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| CA2265495A1 (en) * | 1996-09-13 | 1998-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Non-hormonal method of contraception |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US6867187B2 (en) * | 2000-12-22 | 2005-03-15 | Trustees Of The University Of Pennsylvania | Composition and method for modulating somatolactogenic function |
| EP1325930A1 (de) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Varianten von Säugerprolactin |
| EP1578480A2 (de) * | 2002-12-13 | 2005-09-28 | The Ohio State University | Antagonisten von human-prolactin |
| GB0305790D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Novel Composition |
| KR101206318B1 (ko) * | 2004-10-28 | 2012-11-29 | 교와 핫꼬 기린 가부시키가이샤 | 자궁 내막증 치료제 |
| WO2006089678A2 (en) * | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| ME00588A (en) * | 2006-08-18 | 2011-12-20 | Prlr-specific antibody and uses thereof | |
| CN102711773A (zh) | 2007-05-30 | 2012-10-03 | 奥克兰联合服务有限公司 | 生长激素和相关激素的抑制剂,和其使用方法 |
| EP2025683A1 (de) * | 2007-08-13 | 2009-02-18 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Prolaktinvarianten als Antagonisten des Prolaktinrezeptors |
| EP2332995A1 (de) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralisierende Prolactinrezeptor-Antikörper und deren therapeutische Verwendung |
| WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2009
- 2009-12-10 EP EP09075546A patent/EP2332995A1/de not_active Withdrawn
-
2010
- 2010-11-18 SI SI201031367A patent/SI2510006T1/sl unknown
- 2010-11-18 JP JP2012542436A patent/JP6066474B2/ja active Active
- 2010-11-18 WO PCT/EP2010/067746 patent/WO2011069798A1/en active Application Filing
- 2010-11-18 CN CN201080063269.4A patent/CN102884082B/zh active Active
- 2010-11-18 NZ NZ600512A patent/NZ600512A/en unknown
- 2010-11-18 ME MEP-2016-244A patent/ME02577B/de unknown
- 2010-11-18 WO PCT/EP2010/067740 patent/WO2011069794A1/en active Application Filing
- 2010-11-18 EA EA201200860A patent/EA028678B1/ru not_active IP Right Cessation
- 2010-11-18 EP EP10781882A patent/EP2510005A1/de not_active Withdrawn
- 2010-11-18 US US13/514,994 patent/US20120315276A1/en not_active Abandoned
- 2010-11-18 WO PCT/EP2010/067743 patent/WO2011069796A1/en active Application Filing
- 2010-11-18 WO PCT/EP2010/067744 patent/WO2011069797A1/en active Application Filing
- 2010-11-18 CA CA2783610A patent/CA2783610C/en active Active
- 2010-11-18 AP AP2012006343A patent/AP2012006343A0/xx unknown
- 2010-11-18 IN IN5078DEN2012 patent/IN2012DN05078A/en unknown
- 2010-11-18 PL PL10782255T patent/PL2510006T3/pl unknown
- 2010-11-18 PT PT107822553T patent/PT2510006T/pt unknown
- 2010-11-18 HU HUE10776753A patent/HUE031631T2/en unknown
- 2010-11-18 US US13/514,991 patent/US20120321632A1/en not_active Abandoned
- 2010-11-18 EP EP12192708A patent/EP2567979A1/de not_active Withdrawn
- 2010-11-18 AU AU2010330161A patent/AU2010330161B2/en active Active
- 2010-11-18 WO PCT/EP2010/067742 patent/WO2011069795A1/en active Application Filing
- 2010-11-18 BR BR112012014048-5A patent/BR112012014048B1/pt active IP Right Grant
- 2010-11-18 CN CN2010800633485A patent/CN102741291A/zh active Pending
- 2010-11-18 KR KR1020127017831A patent/KR101765968B1/ko active IP Right Grant
- 2010-11-18 CN CN201080063268XA patent/CN102858801A/zh active Pending
- 2010-11-18 DK DK10776753.5T patent/DK2510002T3/en active
- 2010-11-18 DK DK10782255.3T patent/DK2510006T3/en active
- 2010-11-18 MA MA34951A patent/MA33888B1/fr unknown
- 2010-11-18 EP EP12192722A patent/EP2567980A1/de not_active Withdrawn
- 2010-11-18 CN CN2010800634492A patent/CN102858804A/zh active Pending
- 2010-11-18 CA CA2783651A patent/CA2783651A1/en not_active Abandoned
- 2010-11-18 EP EP12192704A patent/EP2567977A1/de not_active Withdrawn
- 2010-11-18 ES ES10776753.5T patent/ES2603352T3/es active Active
- 2010-11-18 JP JP2012542434A patent/JP2013513363A/ja active Pending
- 2010-11-18 EP EP12192705A patent/EP2567978A1/de not_active Withdrawn
- 2010-11-18 RS RS20170010A patent/RS55589B1/sr unknown
- 2010-11-18 US US13/514,995 patent/US20130022606A1/en not_active Abandoned
- 2010-11-18 MX MX2012006621A patent/MX2012006621A/es unknown
- 2010-11-18 EP EP12192707A patent/EP2570435A1/de not_active Withdrawn
- 2010-11-18 PT PT107767535T patent/PT2510002T/pt unknown
- 2010-11-18 WO PCT/EP2010/067747 patent/WO2011069799A1/en active Application Filing
- 2010-11-18 NZ NZ600511A patent/NZ600511A/en unknown
- 2010-11-18 US US13/514,993 patent/US20130171147A1/en not_active Abandoned
- 2010-11-18 EP EP12192721A patent/EP2570436A1/de not_active Withdrawn
- 2010-11-18 AU AU2010330165A patent/AU2010330165B2/en active Active
- 2010-11-18 SG SG2012041182A patent/SG181513A1/en unknown
- 2010-11-18 LT LTEP10776753.5T patent/LT2510002T/lt unknown
- 2010-11-18 JP JP2012542432A patent/JP2013513361A/ja active Pending
- 2010-11-18 EA EA201200851A patent/EA029327B1/ru not_active IP Right Cessation
- 2010-11-18 JP JP2012542435A patent/JP2013513364A/ja not_active Ceased
- 2010-11-18 CA CA2783654A patent/CA2783654A1/en not_active Abandoned
- 2010-11-18 RS RS20160915A patent/RS55277B1/sr unknown
- 2010-11-18 IN IN5082DEN2012 patent/IN2012DN05082A/en unknown
- 2010-11-18 ES ES10782255.3T patent/ES2610654T3/es active Active
- 2010-11-18 MX MX2012006620A patent/MX339343B/es active IP Right Grant
- 2010-11-18 LT LTEP10782255.3T patent/LT2510006T/lt unknown
- 2010-11-18 EP EP10779014A patent/EP2510003A1/de not_active Withdrawn
- 2010-11-18 JP JP2012542431A patent/JP2013513559A/ja active Pending
- 2010-11-18 PL PL10776753T patent/PL2510002T3/pl unknown
- 2010-11-18 PE PE2012000797A patent/PE20121561A1/es not_active Application Discontinuation
- 2010-11-18 EP EP10782255.3A patent/EP2510006B1/de active Active
- 2010-11-18 CA CA2783514A patent/CA2783514A1/en not_active Abandoned
- 2010-11-18 CA CA2783513A patent/CA2783513C/en active Active
- 2010-11-18 JP JP2012542433A patent/JP2013513362A/ja active Pending
- 2010-11-18 EP EP10781671A patent/EP2510004A1/de not_active Withdrawn
- 2010-11-18 US US13/514,996 patent/US9241989B2/en active Active
- 2010-11-18 PE PE2012000791A patent/PE20121360A1/es not_active Application Discontinuation
- 2010-11-18 HU HUE10782255A patent/HUE030143T2/en unknown
- 2010-11-18 SG SG2012041166A patent/SG181511A1/en unknown
- 2010-11-18 EP EP10784482A patent/EP2510007A1/de not_active Withdrawn
- 2010-11-18 CN CN201080063347.0A patent/CN102947338B/zh active Active
- 2010-11-18 CA CA2783678A patent/CA2783678A1/en not_active Abandoned
- 2010-11-18 CN CN2010800634488A patent/CN102858803A/zh active Pending
- 2010-11-18 KR KR1020127017833A patent/KR101790366B1/ko active IP Right Grant
- 2010-11-18 PE PE2017000782A patent/PE20171134A1/es unknown
- 2010-11-18 EP EP10776753.5A patent/EP2510002B1/de active Active
- 2010-11-18 BR BR112012015852A patent/BR112012015852B8/pt active IP Right Grant
- 2010-11-18 SI SI201031312A patent/SI2510002T1/sl unknown
- 2010-11-18 US US13/514,992 patent/US9649374B2/en active Active
- 2010-12-10 AR ARP100104563A patent/AR079348A1/es active IP Right Grant
- 2010-12-10 TW TW099143330A patent/TW201130506A/zh unknown
- 2010-12-10 AR ARP100104564A patent/AR079349A1/es unknown
- 2010-12-10 TW TW099143327A patent/TW201130504A/zh unknown
- 2010-12-10 TW TW099143332A patent/TWI508744B/zh active
- 2010-12-10 AR ARP100104566A patent/AR079351A1/es unknown
- 2010-12-10 AR ARP100104565A patent/AR079350A1/es unknown
- 2010-12-10 AR ARP100104567A patent/AR079352A1/es active IP Right Grant
- 2010-12-10 TW TW099143326A patent/TW201138817A/zh unknown
- 2010-12-10 TW TW099143328A patent/TWI487536B/zh active
- 2010-12-17 AR ARP100104707A patent/AR079641A1/es unknown
-
2012
- 2012-06-04 IL IL220151A patent/IL220151A0/en active IP Right Grant
- 2012-06-04 IL IL220149A patent/IL220149A/en active IP Right Grant
- 2012-06-07 CU CU2012000093A patent/CU23973B1/es not_active IP Right Cessation
- 2012-06-07 CU CU2012000092A patent/CU20120092A7/es unknown
- 2012-06-08 TN TNP2012000294A patent/TN2012000294A1/en unknown
- 2012-06-08 CR CR20120312A patent/CR20120312A/es unknown
- 2012-06-08 ZA ZA2012/04214A patent/ZA201204214B/en unknown
- 2012-06-08 EC ECSP12011965 patent/ECSP12011965A/es unknown
- 2012-06-08 EC ECSP12011966 patent/ECSP12011966A/es unknown
- 2012-06-08 CL CL2012001539A patent/CL2012001539A1/es unknown
- 2012-06-08 ZA ZA2012/04213A patent/ZA201204213B/en unknown
- 2012-06-08 DO DO2012000160A patent/DOP2012000160A/es unknown
- 2012-06-08 CL CL2012001540A patent/CL2012001540A1/es unknown
- 2012-06-08 DO DO2012000159A patent/DOP2012000159A/es unknown
- 2012-06-08 GT GT201200186A patent/GT201200186A/es unknown
- 2012-06-08 CR CR20120310A patent/CR20120310A/es unknown
-
2013
- 2013-07-02 HK HK13107690.3A patent/HK1180354A1/xx unknown
- 2013-07-10 HK HK13108063.0A patent/HK1180700A1/xx unknown
-
2015
- 2015-07-03 JP JP2015134286A patent/JP6199930B2/ja active Active
-
2016
- 2016-10-26 HR HRP20161401TT patent/HRP20161401T1/hr unknown
- 2016-10-31 CY CY20161101101T patent/CY1118209T1/el unknown
-
2017
- 2017-01-05 HR HRP20170016TT patent/HRP20170016T1/hr unknown
- 2017-01-10 CY CY20171100030T patent/CY1118407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2012006343A0 (en) | Neutralizing prolactin receptor antibodies and their therapeutic use. | |
| HK1220981A1 (zh) | 人巨細胞病毒中和抗體及其應用 | |
| IL226399A0 (en) | Human antibodies to the glucagon receptor | |
| PL2949666T3 (pl) | Ludzkie przeciwciała przeciwko alfa-synukleinie | |
| IL221620A (en) | Antagonist antibodies against the interleukin receptor 7 and methods for their use | |
| EP2475683A4 (de) | Glucagonrezeptor-antikörper ihre verwendung | |
| EP2207803A4 (de) | Cd9-spezifische menschliche antikörper | |
| HK1195081A1 (zh) | 中和性促乳素受體抗體 及其治療用途 | |
| GB0815788D0 (en) | Therapeutic antibodies | |
| EP2548893A4 (de) | Doppelantagonist für tnf-alpha und il-21 zur vorbeugung und behandlung von autoimmunerkrankungen | |
| EP2324059A4 (de) | Therapeutische anti-pamp-antikörper | |
| GB0902916D0 (en) | Antibody therapy | |
| HRP20190159T1 (hr) | Antitijela humanog anti-alfa-sinukleina | |
| IL226635B (en) | Human anti-sod1 antibodies |